Skip to main content

Stryker Value Stock - Dividend - Research Selection

Stryker

ISIN: US8636671013 , WKN: 864952

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Zimmer Biomet: Execution Remains The Sticking Point

2025-12-23
Zimmer Biomet shows value with new products and M&A, but execution risks remain. Click here to read my latest analysis of ZBH stock.

Citi Cuts Stryker (SYK) PT, Maintains Buy Amid Leadership Changes

2025-12-22
Stryker Corporation (NYSE:SYK) is one of the best healthcare AI stocks to buy now. On December 11, Citi cut the price target on Stryker Corporation (NYSE:SYK) from $455 to $420, while maintaining a Buy rating on the shares. This adjustment, the firm said, is part of a sector-wide adjustment as it formulates its 2026 outlook. […]

Citizens Upgrades Stryker (SYK)

2025-12-20

Why Analysts Think Stryker’s Story Is Shifting As Valuation Gets More Sensitive To Growth

2025-12-19
Stryker's fair value estimate has been nudged lower, slipping from about $433.19 per share to roughly $427.66 as analysts recalibrate their expectations. This slight reset reflects a modestly higher discount rate alongside a small uptick in assumed revenue growth, capturing both a cautious MedTech backdrop and confidence in Stryker's durable top line trajectory. Read on to see how investors can track these evolving assumptions and monitor potential narrative shifts around the stock. Stay...

Circle Internet initiated, Lyft downgraded: Wall Street's top analyst calls

2025-12-19
Circle Internet initiated, Lyft downgraded: Wall Street's top analyst calls

Here Are Friday’s Top Wall Street Analyst Research Calls: Birkenstock, Coreweave, Lockheed Martin, Lyft, Paccar, Stryker, Synaptics, and More

2025-12-19
Pre-Market Stock Futures: Futures are trading higher on Friday as we prepare for the holiday-shortened week leading up to Christmas, following a solid risk-on Thursday. The Consumer Price Index print for November lit a fire under stocks as it came in much lower than expected at 2.7%. However, many on Wall Street were quick to ... Here Are Friday’s Top Wall Street Analyst Research Calls: Birkenstock, Coreweave, Lockheed Martin, Lyft, Paccar, Stryker, Synaptics, and More

Truist Securities Maintains Stryker (SYK) Hold Recommendation

2025-12-19

What Makes Stryker Corp. (SYK) a High-Quality, Defensive Compounder?

2025-12-18
Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund focuses on owning a concentrated portfolio of U.S. large-cap stocks. For the third quarter of 2025, the fund reported a net return of 7.46% outperforming its benchmark, the […]

Will Direct Distribution in Southern Europe Boost ISRG's Margins?

2025-12-18
ISRG plans a 2026 shift to direct distribution in Italy, Spain, and Portugal, aiming to lift margins by capturing distributor economics with execution risk.

What Stryker (SYK)'s Dividend Hike and Leadership Shift Means For Shareholders

2025-12-18
Stryker recently announced that its Board of Directors approved a quarterly dividend of US$0.88 per share, payable on January 30, 2026, to shareholders of record as of December 31, 2025, reflecting a 4.8% increase from the prior year and quarter. At the same time, Stryker is reshaping its leadership bench for 2026 and beyond, elevating long-tenured executives Spencer Stiles to President and COO and Dylan Crotty to Group President of Orthopaedics, signaling continuity in operations and focus...